Home › Lymphoma › California › Orange
Lymphoma clinical trials in Orange, CA
4 studies for Lymphoma are looking for participants at sites in and around Orange (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
RecruitingPhase 1
- University of California, Irvine Medical Center - Hematology/Oncology, Orange
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
RecruitingPhase 1/2
- Children's Hospital of Orange County, Orange
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
RecruitingPhase 3
- University of California, Irvine, Orange
Feasibility Study on the Effect of a Methionine-Reduced Diet on Serum Levels in Pts w/ Solid Tumors
RecruitingEarly phase 1
- Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange
About Lymphoma
Lymphoma is a cancer affecting the immune system. Hodgkins Lymphoma and Non Hodgkins Lymphoma are types of lymphoma. Learn about symptoms and treatments.
More about Lymphoma on MedlinePlus
Lymphoma trials in other cities
- Houston, TX34 studies
- Boston, MA33 studies
- New York City, NY33 studies
- Washington, DC23 studies
- Baldwin Park, CA21 studies
- Chicago, IL20 studies
- Durham, NC17 studies
- St. Louis, MO15 studies
- Philadelphia, PA15 studies
- Cleveland, OH14 studies
- Edison, NJ12 studies
- Atlanta, GA12 studies
Other studies in Orange
- Non-Small Cell Lung Cancer25 studies
- Metastatic Cancer20 studies
- Colorectal Cancer16 studies
- Ovarian Cancer16 studies
- Pancreatic Cancer15 studies
- Breast Cancer14 studies
- Lung Cancer14 studies
- Prostate Cancer14 studies
- Liver Cancer (Hepatocellular Carcinoma)14 studies
- Melanoma14 studies
- Acute Myeloid Leukemia13 studies
- Cancer (all types)13 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.